Cargando…
Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes
BACKGROUND: We compared the efficacy of postoperative chemoradiation (POCRT) and surgery alone (SA) in patients with stage II–III esophageal squamous cell carcinoma (ESCC). METHODS: We analyzed the records of 265 patients with stage II–III ESCC who had undergone transthoracic esophagectomy and lymph...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129165/ https://www.ncbi.nlm.nih.gov/pubmed/27766781 http://dx.doi.org/10.1111/1759-7714.12355 |
_version_ | 1782470541988331520 |
---|---|
author | Zou, Bingwen Pang, Jing Liu, Yongmei Xu, Yong Li, Lu Zhou, Lin Zhu, Jiang Huang, Meijuan Wang, Jin Ren, Li Gong, Youlin Lu, You Chen, Longqi Peng, Feng |
author_facet | Zou, Bingwen Pang, Jing Liu, Yongmei Xu, Yong Li, Lu Zhou, Lin Zhu, Jiang Huang, Meijuan Wang, Jin Ren, Li Gong, Youlin Lu, You Chen, Longqi Peng, Feng |
author_sort | Zou, Bingwen |
collection | PubMed |
description | BACKGROUND: We compared the efficacy of postoperative chemoradiation (POCRT) and surgery alone (SA) in patients with stage II–III esophageal squamous cell carcinoma (ESCC). METHODS: We analyzed the records of 265 patients with stage II–III ESCC who had undergone transthoracic esophagectomy and lymphadenectomy; 105 patients received POCRT, while 160 had SA. RESULTS: The median disease‐free survival (DFS) of the whole cohort was 22 months (95% confidence interval [CI], 19.2–24.8), while the median overall survival (OS) was 29 months (95% CI 25.5–32.5). The median DFS of the SA group was 21 months (95% CI 17.9–24.0), while that of the POCRT group was 29 months (95% CI 18.8–31.2; P = 0.048). Consistently, patients in the POCRT group had significantly longer median OS than patients in the SA group (34 vs. 26 months, respectively). Subgroup analysis showed that in patients with positive lymph nodes, pathological stage III, T3–4 stage, and poorly differentiated carcinoma, POCRT was apparently more effective than SA at improving OS and decreasing the rates of local recurrence and distant metastasis. Multivariate analysis demonstrated that lymph node involvement and treatment with POCRT were independent prognostic factors. CONCLUSION: Compared with SA, POCRT may be more effective in improving OS and decreasing the rates of local recurrence and distant metastasis, particularly in stage III or positive lymph node stage II–III ESCC patients. |
format | Online Article Text |
id | pubmed-5129165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51291652016-12-12 Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes Zou, Bingwen Pang, Jing Liu, Yongmei Xu, Yong Li, Lu Zhou, Lin Zhu, Jiang Huang, Meijuan Wang, Jin Ren, Li Gong, Youlin Lu, You Chen, Longqi Peng, Feng Thorac Cancer Original Articles BACKGROUND: We compared the efficacy of postoperative chemoradiation (POCRT) and surgery alone (SA) in patients with stage II–III esophageal squamous cell carcinoma (ESCC). METHODS: We analyzed the records of 265 patients with stage II–III ESCC who had undergone transthoracic esophagectomy and lymphadenectomy; 105 patients received POCRT, while 160 had SA. RESULTS: The median disease‐free survival (DFS) of the whole cohort was 22 months (95% confidence interval [CI], 19.2–24.8), while the median overall survival (OS) was 29 months (95% CI 25.5–32.5). The median DFS of the SA group was 21 months (95% CI 17.9–24.0), while that of the POCRT group was 29 months (95% CI 18.8–31.2; P = 0.048). Consistently, patients in the POCRT group had significantly longer median OS than patients in the SA group (34 vs. 26 months, respectively). Subgroup analysis showed that in patients with positive lymph nodes, pathological stage III, T3–4 stage, and poorly differentiated carcinoma, POCRT was apparently more effective than SA at improving OS and decreasing the rates of local recurrence and distant metastasis. Multivariate analysis demonstrated that lymph node involvement and treatment with POCRT were independent prognostic factors. CONCLUSION: Compared with SA, POCRT may be more effective in improving OS and decreasing the rates of local recurrence and distant metastasis, particularly in stage III or positive lymph node stage II–III ESCC patients. John Wiley & Sons Australia, Ltd 2016-05-06 2016-09 /pmc/articles/PMC5129165/ /pubmed/27766781 http://dx.doi.org/10.1111/1759-7714.12355 Text en © 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Zou, Bingwen Pang, Jing Liu, Yongmei Xu, Yong Li, Lu Zhou, Lin Zhu, Jiang Huang, Meijuan Wang, Jin Ren, Li Gong, Youlin Lu, You Chen, Longqi Peng, Feng Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes |
title | Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes |
title_full | Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes |
title_fullStr | Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes |
title_full_unstemmed | Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes |
title_short | Postoperative chemoradiotherapy improves survival in patients with stage II–III esophageal squamous cell carcinoma: An analysis of clinical outcomes |
title_sort | postoperative chemoradiotherapy improves survival in patients with stage ii–iii esophageal squamous cell carcinoma: an analysis of clinical outcomes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129165/ https://www.ncbi.nlm.nih.gov/pubmed/27766781 http://dx.doi.org/10.1111/1759-7714.12355 |
work_keys_str_mv | AT zoubingwen postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT pangjing postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT liuyongmei postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT xuyong postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT lilu postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT zhoulin postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT zhujiang postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT huangmeijuan postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT wangjin postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT renli postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT gongyoulin postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT luyou postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT chenlongqi postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes AT pengfeng postoperativechemoradiotherapyimprovessurvivalinpatientswithstageiiiiiesophagealsquamouscellcarcinomaananalysisofclinicaloutcomes |